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Recent advances in our understanding of proallergic cytokines and group 2 innate lymphoid cells (ILC2s)
indicate their critical roles in type 2 immunity-mediated disorders. Proallergic cytokines, interleukin (IL)-
25, IL-33, and thymic stromal lymphopoietin, are released from epithelial cells in inﬂamed tissues and
drive type 2 inﬂammation by acting on innate and acquired immune systems. ILC2s are an innate im-
mune population that responds to proallergic cytokines by producing type 2 cytokines. In line with
allergic disorders in the lung, skin, and intestine, emerging evidence suggests the involvement of
proallergic cytokines and ILC2s in allergic nasal diseases such as chronic rhinosinusitis with polyps
(CRSwNP), allergic fungal rhinosinusitis, and allergic rhinitis (AR). In CRSwNP patients, both proallergic
cytokine levels and ILC2s frequency are increased in the nasal mucosa. Increased proallergic cytokine
levels correlate with poorer disease outcomes in CRSwNP. Levels of nasal proallergic cytokines are also
elevated in AR patients. In addition, animal studies demonstrate that cytokines are essential for the
development of AR. It is becoming clear that the proallergic cytokine/ILC2s axis participates in allergic
diseases by multiple mechanisms dependent upon the inﬂammatory context. Thus, a thorough under-
standing of these cytokines and ILC2s including their tissue- and disease-speciﬁc roles is essential for
targeting the pathways to achieve therapeutic applications.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Recent major steps forward in our understanding of type 2 im-
mune responses must include the discovery of three proallergic
cytokines, interleukin (IL)-25 (also known as IL-17E), IL-33 (also
known as IL-1F11), and thymic stromal lymphopoietin (TSLP), as
well as a potent innate type 2 cytokine producer, group 2 innate
lymphoid cells (ILC2s). IL-25, IL-33, and TSLP are produced byeases, Institute for Advanced
dical Zoology, Hyogo College
o).
ety of Allergology.
rgology. Production and hosting by Elseepithelial cells in barrier tissues as well as several immune cells in
response to allergen exposure.1 These cytokines both activate den-
dritic cells (DCs) to initiate Th2 responses and stimulate Th2 cells to
enhance Th2 immunity.1 In addition to inducing Th2 acquired im-
mune responses, they also stimulate innate type 2 cells including
basophils, mast cells, eosinophils, and ILC2s.1 Thus, they play pivotal
roles in both “acquired-type allergy”mediated byactivated Th2 cells
and antigen-speciﬁc IgE, and “innate-type allergy” inducedwithout
activation of the acquired immune system.1,2
ILC2s are a heterogeneous population comprising natural helper
cells,3 nuocytes,4 and innate helper type 2 cells,5 all characterized
by a lack of surface lineage markers and the ability to produce large
amounts of type 2 cytokines.6 IL-25, IL-33, and TSLP strongly
enhance ILC2 growth and induce the production of IL-5 and IL-13.6vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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granulocyte-macrophage colony-stimulating factor (GM-CSF), and
amphiregulin.7e10 These cytokines promote eosinophilia, mucus
production, M2 macrophage development, and tissue repair; thus,
ILC2s are important effector cells in type 2 immune responses.6 In
addition to these effector functions, a growing body of evidence
indicates that ILC2s mediate Th2 development by promoting DC
activation11,12 or by directly interacting with CD4þ T cells.8,13
These observations highlight the critical and complex involve-
ment of the IL-25-, IL-33-, and TSLP-ILC2s axes in the development
and exacerbation of allergic inﬂammation. Thus, it is no surprise
that these pathways also have important roles in allergic disorders
of the upper airways. Although little information is available
comparedwith other organs such as the lung, skin, or intestine, here
we summarize the current understanding of the roles of epithelial-
derived proallergic cytokines and ILC2s in nasal allergic diseases,
namely chronic rhinosinusitis (CRS) and allergic rhinitis (AR).
Chronic rhinosinusitis
CRS is a nasal inﬂammatory disease with characteristic symp-
toms including nasal discharge, nasal congestion, facial pain, and
hyposmia or anosmia for 12 weeks or more.14 CRS can be further
divided into two major subtypes, CRS with nasal polyps (CRSwNP)
and CRS without nasal polyps (CRSsNP), characterized by the
presence or absence of polyps.14 CRSwNP often accompanies tissue
eosinophilia and is considered a Th2-dominated disease, while the
immunological phenotype is likely to be skewed towards Th1 in
CRSsNP patients.14 Although CRS is a complex disease and the Th1
vs Th2 classiﬁcation of the CRS subtypes might be an over-
simpliﬁcation,15 emerging evidence supports the signiﬁcant
involvement of epithelial-derived proallergic cytokines and ILC2s
in CRSwNP.
Human ILC2s were ﬁrst isolated from lungs, gut, and inﬂamed
nasal polyps,16 and increased numbers of ILC2s were observed in
the polyps from CRSwNP patients compared with nasal mucosa
from CRSsNP patients or healthy controls.7,16e20 Increased ILC2s
frequencies in sinus mucosa were correlated with worsening nasal
symptoms in CRS patients.20 In addition, the ILC2 population is
concentrated in polyps compared with sinus mucosa of CRSwNP
patients.21 These nasal polyp-derived ILC2s respond to IL-25, IL-33,
and TSLP by producing IL-4, IL-5, IL-9, IL-13 and GM-CSF.7,16,17 Thus,
ILC2s may be an important source for type 2 cytokines in nasal
polyps and contribute to tissue eosinophilia (Fig. 1). Furthermore,
the preferential location of ILC2s in nasal polyps,21 and gene
expression analysis demonstrating that ILC2s express several fac-
tors involved in tissue remodeling,22 suggest these cells contribute
to polyp generation in CRSwNP (Fig. 1).
mRNA levels of IL-33 receptor, ST2 (also known as IL1RL1), and
numbers of ST2þ cells are increased in polyps from CRSwNP or
eosinophilic CRS patients.17,23,24 Furthermore, an association be-
tween ST2 polymorphisms and CRS was reported.25 Among CD45þ
cells in the nasal mucosa from CRSwNP patients, ILC2s were the
dominant source of IL-13 by in vitro stimulation of cells with IL-2
plus IL-33.17 Although some studies have demonstrated that IL33
expression levels were not altered among CRSwNP, CRSsNP, and
healthy controls,17,18,23 an interesting observation indicated that
nasal epithelial cells from treatment-resistant CRSwNP patients
expressed higher levels of IL33 compared with treatment-
responsive CRSwNP patients.26 Therefore, altered IL-33 expres-
sion or an enhanced response of ILC2s to this cytokine in CRSwNP
patients may aggravate disease severity and compromise the efﬁ-
cacy of treatments.
The expression levels of TSLP and TSLPR (also known as CRLF2)
were higher in the nasal mucosa from CRSwNP7,27,28 or eosinophilicCRS29 patients compared with CRSsNP or healthy controls. In
addition, nasal epithelial cells from CRSwNP patients had a greater
up-regulation of TSLP expression in response to stimulation by poly
I:C, a Toll-like receptor (TLR)3 ligand, compared with healthy con-
trols.7 Importantly, TSLP expression levels in nasal mucosa corre-
lated to the polyp scores in CRS patients.29 In addition to the
observation of increased TSLP mRNA transcription, TSLP protein
undergoes proteolytic cleavage by proteases in nasal polyps which
enhances its bioactivity.30 Increased TSLP activity in CRSwNP nasal
mucosa may contribute to increased activation of DCs,28 mast
cells,30 and ILC2s7,16 (Fig. 1). ILC2s from nasal polyps also responded
to IL-25,16 and a study demonstrated elevated IL25 levels in
CRSwNP patients (Fig. 1).31 Although the study did not observe an
association between disease severity and IL33 or TSLP levels, they
showed that increased IL25 levels correlated with poorer computed
tomography (CT) scores in CRSwNP.31
These observations suggest the critical involvement of proal-
lergic cytokines/ILC2s axis in the pathogenesis of CRSwNP.
Although the relative contribution of ILC2s and Th2 cells in the type
2 milieu in CRSwNP is currently not clear, a study demonstrated
that the number of ILC2s and Th2 cells was signiﬁcantly correlated
in nasal mucosa from CRSwNP patients.18 Thus, ILC2s and Th2 cells
may be simultaneously activated in the local allergic environment
as both populations can respond to epithelial-derived proallergic
cytokines.1 Alternatively, they might cross-regulate each other as
the dialogue between ILC2s and CD4þ T cells was demonstrated in
lungs8 and intestines (Fig. 1).13
Allergic fungal rhinosinusitis (AFRS) is an endotype of CRS
caused by bacterial or fungal infection,14,32 and characterized by the
presence of fungal hyphae in mucin in the sinus cavity, and serum
fungi-speciﬁc IgE.14,32 The local elevation of type 2 cytokines, IL-4,
IL-5, and IL-13, is often observed in AFRS; thus the disease is
considered a Th2-dominant type of CRS.14,32 Currently, no study has
directly investigated the role of proallergic cytokines in the path-
ogenesis of AFRS.32 However, because both AFRS and CRSwNP are
linked to type 2 immunity,14,32 and fungi extracts or TLR ligands
(fungal or bacterial accumulation present in AFRS patients) induce
the expression of IL25,33 IL33,17 and TSLP7 in nasal epithelial cells,
epithelial-derived proallergic cytokines and ILC2s may also play
important roles in AFRS analogous to that in CRSwNP. Further study
is required to fully understand the subtype speciﬁc roles of proal-
lergic cytokines and ILC2s in CRS.
Allergic rhinitis
AR is an IgE-mediated type 1 hypersensitivity reaction in nasal
mucosa caused by nasal allergen exposure.34,35 The characteristic
symptoms of AR are sneezing, rhinorrhea, and nasal congestion
caused by IgE-mast-cell-mediated early-phase responses of AR
(5e30 min after allergen exposure).34,35 In addition, type 2 cyto-
kines and chemokines mediate the cellular inﬂux into nasal mu-
cosa, typically eosinophilia, which cause the late-phase responses
of AR (approximately 6e24 h after allergen exposure) resulting in
tissue damage and remodeling.34,35 Because both AR and CRS are
nasal inﬂammatory diseases, they are associated with each other
with an estimated prevalence of AR of 60% in CRS patients.14
Several lines of evidence have indicated increased epithelial
proallergic cytokine levels in AR patients. Three cytokines, IL-25,36
IL-33,37,38 and TSLP36 were detected in the nasal lavage from pa-
tients with house dust mite (HDM)36,37 or Japanese cedar pollen38
AR. IL33,39,40 ST2,40 and TSLP27,41e43 mRNA levels were high in nasal
epithelia from several types of AR patients. CD4þ cells in peripheral
blood mononuclear cells (PBMCs) from AR patients with birch,
grass,44 or Japanese cedar45 pollen sensitization expressed high
levels of IL25R (also known as IL17RB) mRNA.44,45
Fig. 1. Proallergic cytokines and group 2 innate lymphoid cells in chronic rhinosinusitis with nasal polyps. Although the cause of chronic rhinosinusitis with nasal polyps (CRSwNP)
varies among patients, bacterial or fungal infection induces the production of proallergic cytokines from nasal epithelial cells. IL-25, IL-33, and TSLP stimulate group 2 innate
lymphoid cells (ILC2s) to produce type 2 cytokines, IL-5 and IL-13. TSLP activates dendritic cells (DCs) to activate Th2 cells, and contributes to IL-5 production from mast cells.
Because the numbers of ILC2s and Th2 cells are associated in the nasal sinus, these cells might cross-regulate each other. IL-5 and IL-13 induce eosinophilic inﬁltration into the nasal
mucosa. ILC2s might also produce tissue remodeling factors that could be involved in polyp generation during disease.
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morphisms in IL33 locus linked to Japanese cedar pollenosis,38 and
serum IL-33 levels seemed to correlate with disease severity of
grass and/or tree pollen AR.46 In addition, an animal study using
Il33/ mice demonstrated a pivotal role for IL-33 in ragweed-
speciﬁc AR.39 After nasal ragweed pollen challenge of ragweed-
sensitized mice, Il33/ mice showed attenuated sneezing and
eosinophilic and basophilic inﬁltration into the nose with lower
serum ragweed-speciﬁc IgE titers and reduced ragweed-speciﬁc
Th2 cell responses compared with wild-type controls.39 IL-33
augments IgE-mediated histamine release from mast cells and
IgE-independent cytokine and chemokine production from mast
cells and basophils (Fig. 2).39 In addition to gene-targeted mouse
experiments, the treatment of ovalbumin (OVA)-sensitized mice
with anti-IL-33 antibodies at the nasal OVA-challenge phase
attenuated nose scratching behavior and nasal cellular inﬁltration47
in mice, indicating the therapeutic potential of targeting IL-33 in
post-sensitized AR patients.
As for IL-33, polymorphisms in TSLP locus are also associated
with AR,48e50 and nasal TSLP expression levels are linked to disease
severity.42,43 As TSLP is regarded as the master regulator for Th2
development by activating DCs,1 TSLP-responsive CD1cþ DCs are
recruited to nasal mucosa of grass pollen AR patients after allergen
challenge.51 TSLP-activated CD1cþ DCs strongly induce the prolif-
eration of, and type 2 cytokine production from allergen-speciﬁcTh2 cells (Fig. 2).51 An animal study using OVA-sensitized mice
demonstrated that anti-TSLP antibody treatment at the nasal OVA-
challenge phase ameliorated scratching behavior and nasal goblet
cell hyperplasia.52 Thus, analogous to the role of TSLP in asthma
models, TSLP may have a critical role in developing Th2 responses
in nasal mucosa (Fig. 2). Although the relative contribution of IL-33
and TSLP in AR is not clear, a study showed a positive correlation
between IL-33 and TSLP levels in nasal mucosa,18 suggesting that
these cytokines cross-regulate each other either directly or
indirectly.
IL-25 is also detected in nasal lavage from HDM AR patients,36
and a mouse model of OVA-speciﬁc AR demonstrated up-
regulated Il25 mRNA levels in diseased nasal mucosa.53 Allergen
stimulation of basophils from birch or grass pollen AR patients, but
not from healthy controls, up-regulated IL-25R expression on
PBMCs.44 The same study demonstrated that IL-25 stimulation of
basophils inhibited cellular apoptosis and enhanced IgE-induced
degranulation (Fig. 2).44 In addition, IL-25 enhanced poly I:C-
induced TSLP production from primary human nasal epithelial
cells.36
Despite our understanding of the pivotal roles of epithelial-
derived proallergic cytokines in AR pathogenesis, the role of ILC2s
in AR is poorly understood. AR is an IgE- and Th2-dependent dis-
order34,35 and the development of AR was completely abrogated in
Rag2/ mice, which lack both T and B cells but retain ILC2s, when
Fig. 2. Proallergic cytokines and group 2 innate lymphoid cells in allergic rhinitis. Nasal epithelial cells stimulated with allergens produce proallergic cytokines. TSLP activates
dendritic cells (DCs) to drive allergen-speciﬁc Th2 cells. Following IgE crosslinking, IL-33 augments mast cell degranulation and IL-25 augments basophil degranulation, which
enhances the early phase response of allergic rhinitis (AR). IL-33 also induces cytokines and chemokines production frommast cells and basophils, resulting in enhanced local type 2
immune responses. Allergen stimulation of mast cells and basophils induces the rapid release of lipid mediators, such as prostaglandin D2 (PGD2) or leukotriene D4 (LTD4), which
may cause the temporal activation of group 2 innate lymphoid cells (ILC2s). Generation of nasal type 2 milieu results in eosinophilic inﬁltration and mucus production that mediates
the late phase responses of AR.
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that ILC2s alone cannot mediate the symptoms of AR including
tissue eosinophilia,54 which can be induced solely by activating
ILC2s in lungs.55 ILC2s are present in mouse nasal mucosa in the
steady state,54 although ILC2s do not expand in the allergic nasal
mucosa (Y.K., S.A., and T.Y. unpublished observation). In a human
study, the numbers and cytokine-producing activities of ILC2s in
PBMCs from AR patients were comparable to those from healthy
controls, whereas allergic asthma patients showed an increased
number of ILC2s and increased cytokine production from ILC2s in
PBMCs.56 However, another human study of cat allergen-sensitized
AR patients demonstrated an increased ILC2 frequency in PBMCs,
4 h after nasal cat allergen exposure.57 Thus, even though AR
conditions do not affect the state of ILC2s in the nose or periphery,
these cells could be temporarily activated after allergen exposure
and participate in the production of type 2 cytokines collaborating
with other cells, such as Th2 cells, basophils, and mast cells. In
addition to proallergic cytokines, ILC2s were activated by prosta-
glandin D258 or leukotriene D459 rapidly released from basophils
and mast cells by allergen exposure in AR (Fig. 2).34 Because recent
studies have demonstrated the involvement of ILC2s in the devel-
opment of Th2-acquired immunity in lungs,8,11,12 whether this is
also the case in nasal allergy should be investigated. The exact
contribution of ILC2s in AR might be determined by using recently
established mouse models in which the ILC2 population is specif-
ically abrogated.11,60
AR is diagnosed by detecting systemic or local allergen-speciﬁc
IgE in individuals who have rhinitis symptoms.34,35 Rhinitis pa-
tients with negative allergen-speciﬁc IgE are classiﬁed as non-
allergic rhinitis (NAR).61 NAR is a heterogeneous population andsome NAR patients show nasal eosinophilia and/or mastocy-
tosis.62,63 Importantly, NAR patients with eosinophils and/or mast
cells have a lower quality of life and a higher risk for comorbidities
compared with other NAR patients.62,63 Because the presence of
eosinophils or mast cells is reminiscent of type 2 inﬂammation, it is
of interest to investigate the involvement of proallergic cytokines
and ILC2s in NAR with eosinophils and/or mast cells. These path-
ways might activate type 2 inﬂammation without the presence of
speciﬁc Th2-acquired immune responses.
Conclusions
Accumulating evidence indicates that proallergic cytokines and
ILC2s pathways contribute to the pathogenesis of allergic nasal
diseases. Importantly, some studies have shown that proallergic
cytokine levels29,31,42,43,46 or ILC2 numbers20 correlated to the
severity of nasal allergic diseases, implicating the control of these
factors might be beneﬁcial for the treatment of the diseases. In
addition, the proallergic cytokine/ILC2s axis might mediate treat-
ment resistivity in some allergy conditions.26,64 Thus, targeting
proallergic cytokines or ILC2s may improve treatment efﬁcacy,
especially in treatment-resistant patients. In addition to using
cytokine-neutralizing antibodies, recent studies have demon-
strated the potential therapeutic use of small molecule inhibitors
against the proallergic cytokine/ILC2 pathway. For example, a
STAT5 inhibitor, Pimozide, blocked the TSLP/STAT5 pathway and
improved corticosteroid resistance of ILC2s in a lung inﬂammation
model.64 An anti-inﬂammatory lipid, lipoxin A4, inhibited ILC2s
activation.65 Furthermore, ILC2-activating lipid mediators, prosta-
glandin D2 or leukotriene D4, pathways can be inhibited by
K. Matsushita et al. / Allergology International 64 (2015) 235e240 239currently available anti-allergy medicines.66 However, despite the
rapid advances in our understanding of the basic biology of
proallergic cytokines and ILC2s, little is known about their speciﬁc
roles in nasal tissues. Further studies investigating nasal diseases
need to be conducted, and a deeper understanding of proallergic
cytokines and ILC2s in the context of speciﬁc disease conditions
may offer opportunities for the development of novel clinical in-
terventions for nasal allergic diseases.
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